Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Of The Safety, Pharmacokinetics And Anti-tumor Activity Of Talazoparib, Poly (Adp-ribose) Polymerase (Parp) Inhibitor, In Japanese Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 Study Of The Safety, Pharmacokinetics And Anti-tumor Activity Of Talazoparib, Poly (Adp-ribose) Polymerase (Parp) Inhibitor, In Japanese Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Male breast cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 22 Aug 2024 Status changed from active, no longer recruiting to completed.
  • 01 Aug 2022 Planned End Date changed from 1 Jul 2022 to 31 Aug 2024.
  • 23 Jun 2021 Results (n=9) assessing safety, pharmacokinetics and preliminary efficacy of talazoparib in Japanese patients with advanced solid tumors, published in the Investigational New Drugs.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top